PlainPharmaWatch

CMS Open Payments · Program Year 2024

Aurobindo Pharma USA, Inc.

Aurobindo Pharma USA, Inc. reported $120,074.96 across General Payments, Research, and Ownership to 137 physicians and teaching hospitals across 137 transactions.

See the rankings → How this is sourced
$120.1K
All-tracks total
137
Transactions
137
Recipients
#1135
of 1,925 companies

Aurobindo Pharma USA, Inc. reported $120,074.96 across all CMS Open Payments tracks (General + Research + Ownership) to 137 physicians and teaching hospitals in Program Year 2024 - ranking #1135 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $120,074.96, averaging $876.46 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer aurobindo-pharma-usa-inc Aurobindo Pharma USA, Inc.

$120.1K · #1135/1,925 · 0.0% industry · PY2024

  • TOT $120.1K
  • RANK #1135
  • SHARE 0.0%
  • TXN 137
  • RCP 137
  • CAT 3
  • GEN $120.1K
  • TOP1 34.8%
  • PY 2024

Volume peers

Nearest volume peer: Novartis Gene Therapies, Inc. (fka Avexis, Inc.) ($120.0K)

Shalby Advanced Technologies…$120.5KCorMedix Inc.$120.2KAurobindo Pharma USA, Inc. (…$120.1KNovartis Gene Therapies, Inc…$120.0KNuMED for Children, LLC$120.0K
All-tracks payment totals near Aurobindo Pharma USA, Inc. (CMS Open Payments PY2024)

Aurobindo Pharma USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Aurobindo Pharma USA, Inc.

Rank #1135 of 1,925 companies in CMS Open Payments for 2024 belongs to Aurobindo Pharma USA, Inc., which reported $120,074.96 across 137 transactions to 137 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $876.46 per transaction and $876.46 per recipient.

Of the 3 general-payment categories charted below, "Consulting Fee" is the largest at $117.7K across 8 transactions, 98.1% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Consulting Fee" leads Aurobindo Pharma USA, Inc.'s 3-category general-payment breakdown at $117.7K, 98.1% of the reported total.

How Aurobindo Pharma USA, Inc. divides its payments

General-payment categories, ordered by reported total

1. Consulting Fee$117.7K2. Travel and Lodging$1.7K3. Food and Beverage$657.43
Payment Type Amount Transactions
Consulting Fee $117.7K 8
Travel and Lodging $1.7K 40
Food and Beverage $657.43 89

Recipient Concentration in General Payments

The five largest recipient relationships account for $109,746.85 (91.4%) of $120,074.96 in this company's General Payments records across 8 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Aurobindo Pharma USA, Inc.

The five named recipients with the highest reported General Payments from this company

Robert Cotes$41.8KJohn Kane$40.6KDavid Sykes$19.4KKevin ZACHAROFF$4.3KCarol Tamminga$3.7K
  1. 1

    Robert Cotes

    $41,817.39 across 37 reported transactions

  2. 2

    John Kane

    $40,578.83 across 40 reported transactions

  3. 3

    David Sykes

    $19,377.54 across 26 reported transactions

  4. 4

    Kevin ZACHAROFF

    $4,262.14 across 12 reported transactions

  5. 5

    Carol Tamminga

    $3,710.95 across 6 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Aurobindo Pharma USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aurobindo Pharma USA, Inc..

Baylis Medical Technologies Inc.

HHI 2658

Neo Spine USA, Inc.

HHI 2657

Longeviti Neuro Solutions LLC

HHI 2668

Spinecraft, LLC

HHI 2668

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Aurobindo Pharma USA, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Aurobindo Pharma USA, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.